BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khurmi NS, Chang Y, Eric Steidley D, Singer AL, Hewitt WR, Reddy KS, Moss AA, Mathur AK. Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States: Liver Transplantation. Liver Transpl 2018;24:1398-410. [DOI: 10.1002/lt.25055] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Razpotnik M, Bota S, Wimmer P, Hackl M, Lesnik G, Alber H, Peck‐radosavljevic M, Hernandez‐gea V. The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria. Liver Int 2021;41:1058-69. [DOI: 10.1111/liv.14769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Volk ML, Sakr A, De Vera M. Cardiovascular Complications After Liver Transplant: A Shifting Clinical Presentation. Liver Transpl 2018;24:1331-2. [DOI: 10.1002/lt.25324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Fatourou EM, Tsochatzis EA. Management of metabolic syndrome and cardiovascular risk after liver transplantation. Lancet Gastroenterol Hepatol. 2019;4:731-741. [PMID: 31387736 DOI: 10.1016/s2468-1253(19)30181-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
4 Izzy M, Soldatova A, Sun X, Angirekula M, Mara K, Lin G, Watt KD. Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria. Liver Transpl 2021;27:876-86. [PMID: 33533556 DOI: 10.1002/lt.26000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
5 De Luca L, Kalafateli M, Bianchi S, Alasaker N, Buzzetti E, Rodríguez‐perálvarez M, Thorburn D, O'beirne J, Patch D, Leandro G, Westbrook R, Tsochatzis EA. Cardiovascular morbidity and mortality is increased post‐liver transplantation even in recipients with no pre‐existing risk factors. Liver Int 2019;39:1557-65. [DOI: 10.1111/liv.14185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 McCarthy KJ, Motta-Calderon D, Estrada-Roman A, Cajiao KM, Curry MP, Bonder A, Anagnostopoulos AM, Gavin M. Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant - A retrospective cohort analysis. Ann Hepatol 2021;27:100582. [PMID: 34808392 DOI: 10.1016/j.aohep.2021.100582] [Reference Citation Analysis]
7 Barman PM, VanWagner LB. Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions. Hepatology 2021;73:2564-76. [PMID: 33219576 DOI: 10.1002/hep.31647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Levy PE, Khan SS, VanWagner LB. Cardiac evaluation of the kidney or liver transplant candidate. Curr Opin Organ Transplant 2021;26:77-84. [PMID: 33315765 DOI: 10.1097/MOT.0000000000000838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, Di Tanna GL. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020). Pharmacoeconomics 2020;38:1219-36. [PMID: 32812149 DOI: 10.1007/s40273-020-00952-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
10 Sandal S, Chen T, Cantarovich M. The Challenges With the Cardiac Evaluation of Liver and Kidney Transplant Candidates. Transplantation 2020;104:251-8. [DOI: 10.1097/tp.0000000000002951] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Doctorian T, Nandkeolyar S, Fearon C, Nayak S, Tryon D, Sakr A, Stoletniy L, De Vera M, Volk M, Abramov D. Utility of Framingham Score for Optimizing Preoperative Evaluation Among Patients Undergoing Liver Transplant Evaluation. Transplant Proc 2021;53:1616-21. [PMID: 33965242 DOI: 10.1016/j.transproceed.2021.02.026] [Reference Citation Analysis]
12 Sadowski B, Baba T, Rangnekar AS. PRO: Cardiac Catheterization Is the Optimal Strategy for Cardiovascular Risk Stratification in This Patient. Clin Liver Dis (Hoboken) 2021;17:33-6. [PMID: 33552484 DOI: 10.1002/cld.963] [Reference Citation Analysis]
13 Choudhary NS, Saraf N, Saigal S, Soin AS. Long-term Management of the Adult Liver Transplantation Recipients. J Clin Exp Hepatol 2021;11:239-53. [PMID: 33746450 DOI: 10.1016/j.jceh.2020.06.010] [Reference Citation Analysis]
14 Shamaa O, Jafri SM, Shamaa MT, Brown K, Venkat D. Takotsubo Cardiomyopathy Following Liver Transplantation: A Report of 2 Cases. Transplant Proc 2021;53:239-43. [PMID: 32980136 DOI: 10.1016/j.transproceed.2020.07.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mathur AK, Chang YH, Steidley DE, Heilman RL, Wasif N, Etzioni D, Reddy KS, Moss AA. Factors associated with adverse outcomes from cardiovascular events in the kidney transplant population: an analysis of national discharge data, hospital characteristics, and process measures. BMC Nephrol 2019;20:190. [PMID: 31138156 DOI: 10.1186/s12882-019-1390-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]